Dataset from A Phase 1b-2, Open-Label Study of JNJ-68284528, A Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009949
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to characterize safety of JNJ-68284528 and establish the
recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528
(Phase 2).
创建时间：
2025-02-10
